New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.
Publication
, Journal Article
Hamilton, E; Clay, TM; Blackwell, KL
Published in: Cancer Invest
October 2011
A small subset of T cells (gamma-delta T cells) is able to recognize phosphoantigens that are overexpressed in some cancer cells and may selectively target and kill cancer cells with high levels of phosphoantigen. Moreover, nitrogen-containing bisphosphonates, such as zoledronic acid, are able to induce accumulation of specific phosphoantigens in some cancer cells. A recent preclinical study showed that gamma-delta T cells effectively targeted and killed zoledronic acid-treated estrogen-receptor-positive breast cancer cells. These new data provide growing insight into a potential mechanism of action for some of the anticancer activity demonstrated by zoledronic acid in breast cancer clinical trials.
Duke Scholars
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
October 2011
Volume
29
Issue
8
Start / End Page
533 / 541
Location
England
Related Subject Headings
- Zoledronic Acid
- T-Lymphocytes
- Receptors, Antigen, T-Cell, gamma-delta
- Oncology & Carcinogenesis
- Lymphocyte Activation
- Imidazoles
- Humans
- Female
- Diphosphonates
- Breast Neoplasms
Citation
APA
Chicago
ICMJE
MLA
NLM
Hamilton, E., Clay, T. M., & Blackwell, K. L. (2011). New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest, 29(8), 533–541. https://doi.org/10.3109/07357907.2011.605413
Hamilton, Erika, Timothy M. Clay, and Kimberly L. Blackwell. “New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.” Cancer Invest 29, no. 8 (October 2011): 533–41. https://doi.org/10.3109/07357907.2011.605413.
Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest. 2011 Oct;29(8):533–41.
Hamilton, Erika, et al. “New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.” Cancer Invest, vol. 29, no. 8, Oct. 2011, pp. 533–41. Pubmed, doi:10.3109/07357907.2011.605413.
Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest. 2011 Oct;29(8):533–541.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
October 2011
Volume
29
Issue
8
Start / End Page
533 / 541
Location
England
Related Subject Headings
- Zoledronic Acid
- T-Lymphocytes
- Receptors, Antigen, T-Cell, gamma-delta
- Oncology & Carcinogenesis
- Lymphocyte Activation
- Imidazoles
- Humans
- Female
- Diphosphonates
- Breast Neoplasms